These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 1451341)

  • 1. The effects of recombinant human erythropoietin on hemostasis and fibrinolysis in hemodialysis patients.
    Wirtz JJ; van Esser JW; Hamulyák K; Leunissen KM; van Hooff JP
    Clin Nephrol; 1992 Nov; 38(5):277-82. PubMed ID: 1451341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of the treatment with human recombinant erythropoietin on primary hemostasis in uremic patients].
    Cases A; Escolar G; Reverter JC; Garrido M; Ordinas A; López-Pedret J; Castillo R; Revert L
    Med Clin (Barc); 1990 Nov; 95(17):644-7. PubMed ID: 2089202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of recombinant human erythropoietin on hemostasis, fibrinolysis, and blood rheology in autologous blood donors.
    Biesma DH; Bronkhorst PJ; de Groot PG; van de Wiel A; Kraaijenhagen RJ; Marx JJ
    J Lab Clin Med; 1994 Jul; 124(1):42-7. PubMed ID: 8035101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A study of platelet functions, some hemostatic and fibrinolytic parameters in relation to serotonin in hemodialyzed patients under erythropoietin therapy.
    Malyszko J; Malyszko JS; Borawski J; Rydzewski A; Kalinowski M; Azzadin A; Mysliwiec M; Buczko W
    Thromb Res; 1995 Jan; 77(2):133-43. PubMed ID: 7740505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of recombinant human erythropoietin on hematological and hemostatic parameters with special reference to microhemolysis.
    Maurin N; Fitzner S; Fritz H; Gladziwa U; H agel J; Stefanidis I
    Clin Nephrol; 1995 Mar; 43(3):196-200. PubMed ID: 7774078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients.
    Tsao CJ; Kao RH; Cheng TY; Huang CC; Chang SL; Lee FN
    Int J Hematol; 1992 Apr; 55(2):197-203. PubMed ID: 1511168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age dependence of blood fibrinolytic components and the effects of low-dose oral contraceptives on coagulation and fibrinolysis in teenagers.
    Siegbahn A; Ruusuvaara L
    Thromb Haemost; 1988 Dec; 60(3):361-4. PubMed ID: 3149043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
    Pawlak K; Pawlak D; Mysliwiec M
    Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recombinant human erythropoietin (rh-EPO) in chronic, dialysis-dependent renal failure: effects on macro- and microcirculation and hematologic parameters].
    Köhler M; Mörsdorf S; Jung F; Braun B; Waldhausen P; Pindur G; Weber U; Bosslet R; Bambauer R; Jutzler GA
    Beitr Infusionsther; 1990; 26():89-95. PubMed ID: 1703909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of recombinant human erythropoietin (rHuEpo) on the hemostatic system in chronic hemodialysis patients.
    Huraib S; al-Momen AK; Gader AM; Mitwalli A; Sulimani F; Abu-Aisha H
    Clin Nephrol; 1991 Nov; 36(5):252-7. PubMed ID: 1752076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of long-term, low-dose tranexamic acid treatment on platelet dysfunction and haemoglobin levels in haemodialysis patients.
    Sabovic M; Zupan IP; Salobir B; Zupan I; Cernelc P; Lavre J; Vujkovac B
    Thromb Haemost; 2005 Dec; 94(6):1245-50. PubMed ID: 16411401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet (dys)function and plasma plasminogen levels in hemodialysis patients.
    Salobir B; Sabovic M; Zupan IP; Ponikvar JB
    Ther Apher Dial; 2008 Apr; 12(2):133-6. PubMed ID: 18387161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The effect of erythropoietin on fibrinolysis in hemodialyzed patients].
    Opatrný K; Vít L; Opatrná S; Bodláková B; Sulková S; Opatrný K; Krist'an M
    Cas Lek Cesk; 1995 Mar; 134(5):136-8. PubMed ID: 7728837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Long-term hemodialysis and changes in variables of coagulation and fibrinolysis].
    Uchida Y
    Fukuoka Igaku Zasshi; 1991 Nov; 82(11):576-85. PubMed ID: 1774013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Evaluation of platelet function during treatment with recombinant human erythropoietin (r-HuEPO) in patients hemodialyzed and dialyzed peritoneally].
    Janicka L; Majdan M; Dmoszyńska A; Ksiazek A; Berger B; Baranowska E
    Wiad Lek; 1993 Oct; 46(19-20):756-60. PubMed ID: 7975620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. National cooperative rHu erythropoietin study in patients with chronic renal failure: a phase IV multicenter study. Report of National Cooperative rHu Erythropoietin Study Group.
    Nissenson AR
    Am J Kidney Dis; 1991 Oct; 18(4 Suppl 1):24-33. PubMed ID: 1928075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis.
    Mezzano D; Tagle R; Panes O; Pérez M; Downey P; Muñoz B; Aranda E; Barja P; Thambo S; González F; Mezzano S; Pereira J
    Thromb Haemost; 1996 Sep; 76(3):312-21. PubMed ID: 8883263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic and volume changes by recombinant human erythropoietin (rHuEPO) in the treatment of anemic hemodialysis patients.
    Hori K; Onoyama K; Iseki K; Fujimi S; Fujishima M
    Clin Nephrol; 1990 Jun; 33(6):293-8. PubMed ID: 2376091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effects on lymphocytotoxic antibodies and immune reactivity in hemodialysis patients treated with recombinant human erythropoietin.
    Bárány P; Fehrman I; Godoy C
    Clin Nephrol; 1992 Feb; 37(2):90-6. PubMed ID: 1551255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.